Login
Biotechnology Breakthroughs ETFs
- Pininvest Analysis
Because R&D in biotechnology is complex and the rate of drug approval remains uncertain, investment strategies followed by ETFs adopt two distinct models
- broad based funds cast a wide net, as poor performing clinical-stage companies could become tomorrow's stars - with more than 190 holdings, iShares fund IBB/NASDAQ limits risk exposure through diversification
- focused funds, targeting break-through technologies, advanced treatments of rare diseases or clinical-stage research, accept high risk exposure (volatility) in the hope of above average performance
Including funds based on either models as well as leveraged funds, the theme is benchmarked with the iShares NASDAQ Biotechnology ETF IBB/NASDAQ
Our ETF market sector themes present a cross-sectional view of equity trends – in terms of market coverage, size and style. We hope to achieve a fair coverage of ETFs in each category, which is a work in progress
We do not receive any commission or other form of compensation from the providers included in our 'Funds' presentation
Biotechnology Breakthroughs ETFs • Updated:
| Name | Ticker | Exchange | Category | SubCategory | Currency | Cur.Price | AUM | Perf. | Vol. | Risk Contrib. | MDD |
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALPS Medical Breakthroughs | SBIO | NYSEARCA | US Market | 21st Century Focus | USD | 56.90 | 216 M | 34.1% | 44% | 8% | -39% |
|
|
| ARK Invest Genomic Revolution Multi-Sector ETF | ARKG | BATS | Health Care | Biotech | USD | 111.87 | 538 M | 219.2% | 52% | 8% | -35% |
|
|
| Direxion Daily S&P Biotech Bull 3X Shares | LABU | NYSEARCA | Health Care | Biotech | USD | 130.38 | 321 M | 121.5% | 125% | 22% | -76% |
|
|
| First Trust NYSE Arca Biotechnology Index Fund | FBT | NYSEARCA | Health Care | Biotech | USD | 179.39 | 1.7 B | 18.0% | 32% | 5% | -27% |
|
|
| Invesco Dynamic Biotechnology & Genome ETF | PBE | NYSEARCA | Health Care | Biotech | USD | 77.47 | 213 M | 35.5% | 36% | 6% | -31% |
|
|
| iShares Evolved US Innovative Healthcare ETF | IEIH | BATS | Health Care | Biotech | USD | 34.49 | 5.3 M | 21.1% | 28% | 5% | -22% |
|
|
| iShares Nasdaq Biotechnology | IBB | NASDAQ | by Sector | Health Care | USD | 164.83 | 7.0 B | 35.5% | 33% | 6% | -24% |
|
|
| Loncar Cancer Immunotherapy ETF | CNCR | NASDAQ | Health Care | Biotech | USD | 35.15 | 38 M | 51.2% | 42% | 7% | -32% |
|
|
| Principal Healthcare Innovators Index ETF | BTEC | NASDAQ | Health Care | Biotech | USD | 64.67 | 57 M | 63.9% | 39% | 7% | -36% |
|
|
| ProShares Ultra Nasdaq Biotechnology | BIB | NASDAQ | Leveraged | by Sector | USD | 101.92 | 152 M | 62.1% | 69% | 12% | -45% |
|
|
| ProShares UltraShort Nasdaq Biotechnology | BIS | NASDAQ | Inverse | by Sector | USD | 19.76 | 22 M | -62.1% | 66% | -11% | -74% |
|
|
| SPDR S&P Biotech ETF | XBI | NYSEARCA | Health Care | Biotech | USD | 154.22 | 3.9 B | 60.5% | 41% | 7% | -33% |
|
|
| VanEck Vectors® Biotech ETF | BBH | NASDAQ | Health Care | Biotech | USD | 184.24 | 334 M | 31.7% | 31% | 5% | -21% |
|
|
| Virtus LifeSci Biotech Clinical Trials ETF | BBC | NYSEARCA | Health Care | Biotech | USD | 55.01 | 32 M | 44.0% | 45% | 8% | -39% |
|
|
| Virtus LifeSci Biotech Products ETF | BBP | NYSEARCA | Health Care | Biotech | USD | 56.94 | 25 M | 29.3% | 37% | 6% | -30% |
|